Hyderabad based Sathguru Management Consultants in association with Confederation of Indian Industry recently released a white paper on vaccine market scenario in India. In the same context, Ms Pushpa Vijayraghavan, Director, Sathguru shared her views on the critical aspects of Indian vaccine market in an exclusive chat with the BioVoice News. Read the detailed interview below:
What are the key ingredients for success of the vaccine industry in India? Please list out the top five milestones of the Indian vaccine industry so far?
The vaccine industry is driven by its capability to supply high volume yet high quality vaccines for addressing global public health needs. The industry has established a high reputation for doing so by repeatedly accomplishing this for several established and emerging vaccines. Indian vaccine companies have excelled at successfully collaborating with global academic and corporate partners for technology access and product development, been adept at adopting new technologies and working with global public health authorities to proactively address immunization priorities. Lastly, an active and critical role has been played by the Indian Government and regulator. Having a National Regulatory Authority recognized by WHO has enabled several Indian companies to wade through WHO prequalification process efficiently and participate in global procurement processes.
The Indian vaccine industry has time and again, broken affordability barriers, addressed technology challenges and has earned India a special place in the global arena. Noteworthy achievements of the industry include:
Addressing close to 100 percent of Indian immunization needs with affordable yet technically advanced vaccines produced domestically. There is minimal import dependency and India is largely self-sufficient for vaccines for the national immunization program, a stellar Make-in-India success story chartered over the last two decades.
Proactive technology adoption and ensuring Indians have access to vaccines that are not affordable but are also contemporary – Shantha Biotech and Bharat Biotech’s indigenous Hepatitis B vaccine (the first recombinant vaccines to be produced in India) which brought down the vaccine cost from $ 23 a dose to $1 a dose. Similarly, the industry has repeated this success for pentavalent vaccines, more recently the rotavirus vaccine and is currently in the process of doing so for the PCV vaccine.
Extending the breakthrough cost and affordability advantage to the poorest countries in the world – A great illustration is Serum Institute’s Meningococcal A vaccine which now covers 100 percent of GAVI supply of 70 million doses for 15 countries. Prior to Serum, the vaccine was supplied only by multinationals producing in high cost countries and was not affordable to majority of the underdeveloped and developing world where it was needed most. India accounted for more than 60 percent of the vaccines supplied to GAVI in 2014 and supplies more than 80 percent of GAVI procurement for 4 vaccines.
“Our analysis indicates that the industry grew to approximately $1 billion in 2015 with a robust CAGR of 25 percent between 2011 and 2015. Exports are the dominant revenue source for Indian vaccine industry today, accounting for a dominant 69 percent share in value”
How has been the growth of the sector so far and the prediction for next few years?
Our analysis indicates that the industry grew to approximately $1 billion in 2015 with a robust CAGR of 25 percent between 2011 and 2015. Exports are the dominant revenue source for Indian vaccine industry today, accounting for a dominant 69 percent share in value.
We expect this robust growth to be sustained with support from increasing public awareness and high government focus on enhancing vaccination coverage. Private market for discretionary vaccines has also been rapidly growing and we expect the trend to continue for select vaccines where high perception of clinical benefit will drive increased market penetration.
Why don’t we find many more vaccine startups coming up while the market share is mostly held by few players?
Both technology and capital requirements are significant barriers to entry for startups in the segment. Most of the current vaccines are technologically very complex and even leading Indian companies with in-house research capacity are leaning on partnerships to gain technology access. Even where a startup has a technology advantage, the capital requirements are hard to surmount and serve as a significant deterrent. While initial proof of concept funding in the form of non-dilutive grants is now available to innovators, subsequent rounds of funding for clinical validation are hard to access given the continuing paucity of risk capital for biotech product development and the co-funding requirements of grants.
How do you react to the statements that vaccine industry is a bubble created by lobbyists to earn bucks? There are also few who say that immunization campaigns is marketing for MNCs?
There is global evidence on impact of vaccines in reducing disease burden and the health economics are well established. In a high transmissibility environment such as India, vaccines are an import part of the Government’s arsenal to address the looming problem of communicable diseases. The polio vaccine success in India is globally recognized as a landmark effort that has successfully eradicated a once dreaded disease. While I strongly believe that public health stakeholders should not be deterred by such comments, I would also recommend that we adopt a data driven approach to putting any such concerns to rest. As a country, we need to improve our focus on health economics and impact measurement. Such a data driven approach will put any concerns to rest on criticality of immunization programs for public health concerns where it is an appropriate measure.
We should also assess if the specific products we are using in the immunization programs are economically effective in addressing our goals and means to do so more effectively. A great example could be the BCG vaccine that has been used for prevention of TB. It will be a worthwhile for us to assess economic merit of a more effective TB vaccine and this would justify renewed and significantly higher investments in a critical research area.
Lastly, on private vaccines that are now driven more by a pharma styled sales approach, the clinical utility could be debated in several cases. However, as these are out of net of public expenditure in a largely out of pocket market, these are less likely to be part of this debate.
“Eliminating redundancies in the regulatory process and creating efficiency in the approval pathway is critical to ensure that the country realizes benefits of the current pipeline of high value vaccines”